BioPharma

The National Disability Insurance Scheme continued to grow at a rapid rate last year, driven by a 12 per cent increase in participation. However, another indicator suggests tighter management and recent reforms could be slowly moderating the program's growth.

New Zealand's Coalition Government has welcomed confirmation that two major medical conferences will be held in the country in 2026 after the lifting of an advertising ban. 

The Trump administration has revealed its hand on using trade agreements and levers to secure outcomes on pharmaceuticals. In short, it amounts to not very much.

Health Minister Mark Butler has restated his commitment to reforming Australia's use of health technology assessment, saying he looks forward to "getting his teeth into it".

Brandon BioCatalyst has welcomed the inclusion of its national biotechnology incubator, CUREator, in a new $100 million program funded by the Australian Government's Medical Research Future Fund.

Health Minister Mark Butler has launched the Cancer Australia Research Initiative, a new program designed to address emerging needs in cancer research.

Imugene (ASX:IMU) has announced it has received firm commitments from institutional and sophisticated investors for a $22.5 million placement and is launching a share purchase plan for existing eligible shareholders to raise up to $15 million.

Lumos Diagnostics (ASX:LDX) has signed an exclusive US distribution and supply agreement for FebriDx, valued at up to US$317 million (approximately AUD$487 million), with PHASE Scientific International.

Australian clinical-stage biotechnology company Noxopharm (ASX:NOX) has announced the administration of the first SOF-SKN dose in the HERACLES trial.

Over 1,000 professionals from across the life sciences sector have already taken part in On Q Recruitment's 2025 Salary and Job Market Survey.

Viral Vector Manufacturing Facility and Cell Therapies have signed an MoU to explore strategic collaboration opportunities aimed at strengthening the onshore development and manufacture of Advanced Therapy Medicinal Products.

This publication argues that the ethical problem lies in the decision-making framework that denies human rights to individuals. There is no human right to being denied funded access to an approved treatment because other patients are denied on the same basis.